Cost Effectiveness of Hepatitis B Vaccination at HIV Counseling and Testing Sites

American Journal of Preventive Medicine

Volumn 30, Issue 6, 2006, Pages

  Kim, Sun Young ^a   Billah, Kaafee ^c   Lieu, Tracy A ^a,b   Weinstein, Milton C ^a  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b HARVARD PILGRIM HEALTH CARE   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENERGIX B; HEPATITIS B ANTIBODY; HEPATITIS B CORE ANTIGEN; RECOMBINANT HEPATITIS B VACCINE; UNCLASSIFIED DRUG;

ADULT; ADULTHOOD; ARTICLE; CLINICAL ASSESSMENT; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COUNSELING; ECONOMIC ASPECT; EVALUATION; FEMALE; GROUPS BY AGE; HEALTH CARE COST; HEALTH CENTER; HEALTH SERVICE; HEPATITIS B; HIV EDUCATION; HUMAN; HYPOTHESIS; INCIDENCE; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; MEDICAL CARE; MEDICAL DECISION MAKING; MODEL; POPULATION RESEARCH; PREVALENCE; QUALITY OF LIFE; SCREENING TEST; SEXUALLY TRANSMITTED DISEASE; SOCIETY; TIME; TRAVEL; UNITED STATES; VACCINATION;

EID: 33646426438     PISSN: 07493797     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amepre.2006.01.017     Document Type: Article

References (61)

1. Centers for Disease Control and Prevention. Incidence of acute hepatitis B-United States. MMWR Morb Mortal Wkly Rep 52 (2004) 1252-1254
2. Goldstein S.T., Alter M.J., Williams I.T., et al. Incidence and risk factors for acute hepatitis B in the United States, 1982-1998. implications for vaccination programs. J Infect Dis 185 (2002) 713-719
3. Beech B.M., Myers L., and Beech D.J. Hepatitis B and C infections among homeless adolescents. Fam Community Health 25 2 (2002) 28-36
4. Charuvastra A., Stein J., Schwartzapfel B., et al. Hepatitis B vaccination practices in state and federal prisons. Public Health Rep 116 (2001) 203-209
5. Rhodes S.D., and Hergenrather K.C. Exploring hepatitis B vaccination acceptance among young men who have sex with men. facilitators and barriers. Prev Med 35 (2002) 128-134
6. Wilson B.C., Moyer L., Schmid G., et al. Hepatitis B vaccination in sexually transmitted disease (STD) clinics. a survey of STD programs. Sex Transm Dis 28 (2001) 148-152
7. Mast E.E., Williams I.T., Alter M.J., and Margolis H.S. Hepatitis B vaccination of adolescent and adult high-risk groups in the United States. Vaccine 16 suppl (1998) S27-S29
8. Centers for Disease Control. Recommendations for protection against viral hepatitis. MMWR Morb Mortal Wkly Rep 34 (1985) 313-324 329-35
9. Centers for Disease Control, and Recommendation of the Immunization Practices Advisory Committee (ACIP). Inactivated hepatitis B virus vaccine. MMWR Morb Mortal Wkly Rep 31 (1982) 317-322 327-8
10. Recommendations of the Immunization Practices Advisory Committee (ACIP). Hepatitis B virus. a comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination. MMWR Recomm Rep 40 RR-13 (1991) 1-25
11. Centers for Disease Control. Update. recommendations to prevent hepatitis B virus transmission-United States. MMWR Morb Mortal Wkly Rep 44 (1995) 574-575
12. Centers for Disease Control. Update. recommendations to prevent hepatitis B virus transmission-United States. MMWR Morb Mortal Wkly Rep 48 (1999) 33-34
13. Centers for Disease Control. Hepatitis B vaccination-United States, 1982-2002. MMWR Morb Mortal Wkly Rep 51 (2002) 549-552 563
14. Rich J.D., Ching C.G., Lally M.A., et al. A review of the case for hepatitis B vaccination of high-risk adults. Am J Med 114 (2003) 316-318
15. U.S. Department of Health and Human Services. Healthy People 2010. With understanding and improving health and objectives for improving health. 2nd ed. (2000), U.S. Government Printing Office, Washington DC November
16. Weinbaum C., Lyerla R., Margolis H.S., and Centers for Disease Control and Prevention. Prevention and control of infections with hepatitis viruses in correctional settings. [published erratum appears in MMWR Recomm Rep 2003;52:205-14]. MMWR Recomm Rep 52 RR-1 (2003) 1-36 quiz CE1-4
17. Pisu M., Meltzer M., and Lyerla R. Cost-effectiveness of hepatitis B vaccination of prison inmates. Vaccine 21 (2002) 312-321
18. Centers for Disease Control and Prevention. Hepatitis B vaccination for injection drug users-Pierce County, Washington, 2000. MMWR Morb Mortal Wkly Rep 50 (2001) 388-390 399
19. Jacobs R.J., Rosenthal P., and Meyerhoff A.S. Cost effectiveness of hepatitis A/B versus hepatitis B vaccination for U.S.prison inmates. Vaccine 22 (2004) 1241-1248
20. Centers for Disease Control and Prevention. Hepatitis B vaccination among high-risk adolescents and adults-San Diego, California, 1998-2001. MMWR Morb Mortal Wkly Rep 51 (2002) 618-621
21. Centers for Disease Control and Prevention. HIV counseling and testing in publicly funded sites Annual Report 1997 and 1998 (2001), Centers for Disease Control and Prevention, Atlanta GA
22. Centers for Disease Control and Prevention. HIV counseling and testing system. Version 4.0 (1999), National Center for HIV, STD, and TB Prevention, Atlanta GA
23. EASL International Consensus Conference on Hepatitis B. 13-14 September, 2002 Geneva, Switzerland. Consensus statement (long version). J Hepatol 39 (2003) S3-S25 (suppl 1)
24. Margolis H.S., Coleman P.J., Brown R.E., Mast E.E., Sheingold S.H., and Arevalo J.A. Prevention of hepatitis B virus transmission by immunization. An economic analysis of current recommendations. JAMA 274 (1995) 1201-1208
25. The Organ Procurement and Transplantation Network. Available at: http://www.OPTN.org. Accessed February 17, 2005.
26. 2003 Annual Report of the U.S. Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients: transplant data 1993-2002: HHS/HRSA/OSP/DOT; UNOS; URREA.
27. Karvountzis G., Redeker A., and Peters R. Long term follow-up studies of patients surviving fulminant viral hepatitis. Gastroenterology 67 (1974) 870-877
28. Sampliner R.E., Hamilton F.A., Iseri O.A., Tabor E., and Boitnott J. The liver histology and frequency of clearance of the hepatitis B surface antigen (HBsAg) in chronic carriers. Am J Med Sci 277 (1979) 17-22
29. Wong J., Koff R., Tine F., and Pauker S. Cost-effectiveness of interferon-alpha2b treatment for hepatitis B e Antigen-Positive Chronic Hepatitis B. Ann Intern Med 122 (1995) 664-675
30. Dienstag J.L., Schiff E.R., Wright T.L., et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 341 (1999) 1256-1263
31. Hughes W., Barr A., Dow B., Follett A., and Barbara A. A multicentre assessment of the specificity of ten anti-HBc screening tests. Transfus Med 5 (1995) 225-230
32. Weber B., Michl U., Muhlacher A., Paggi G., and Bossi V. Evaluation of the new automated enzymun-test anti-HBc plus for the detection of hepatitis B virus core antibody. Intervirology 41 (1998) 17-23
33. Spronk A., Schmidt L., Krenc C., et al. Improvements in detection of antibody to hepatitis B core antigen by treating specimens with reducing agent in an automated microparticle enzyme immunoassay. J Clin Microbiol 29 (1991) 611-616
34. Salomon J.A., Weinstein M.C., Hammitt J.K., and Goldie S.J. Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population. JAMA 290 (2003) 228-237
35. Lok A., and McMahon B. AASLD practice guideline, chronic hepatitis B. update of recommendations. Hepatology 39 3 (2004) 1-5
36. Hsu Y.-S., Chien R.-N., Yeh C.-T., et al. Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology 35 (2002) 1522-1527
37. Crowley S.J., Tognarini D., Desmond P.V., and Lees M. Cost-effectiveness analysis of lamivudine for the treatment of chronic hepatitis B. Pharmacoeconomics 17 (2000) 409-427
38. Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines 2002. MMWR Recomm Rep 51 RR-6 (2002) 1-78
39. Andre F.E. Summary of safety and efficacy data on a yeast-derived hepatitis B vaccine. Am J Med 87 3A (1989) 14S-20
40. Jilg W., and Deinhard F. Results of immunization with a recombinant yeast-derived hepatitis B vaccine. J Infect 13 suppl A (1986) 47-51
41. Hadler S.C., Francis D.P., Maynard J.E., et al. Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men. N Engl J Med 315 (1986) 209-214
42. European Consensus Group on Hepatitis B Immunity. Are booster immunizations needed for lifelong hepatitis B immunity?. Lancet 355 (2000) 561-565
43. Yuen M., Ling W., Chan A., and Wong D. 18-year follow-up study of a prospective randomized trial of hepatitis B vaccinations without booster doses in children. Clin Gastroenterol Hepatol 2 (2004) 941-945
44. Beutels P. Economic evaluations of hepatitis B immunization. a global review of recent studies (1994-2000). Health Econ 10 (2001) 751-774
45. Centers for Disease Control and Prevention. Update. expanded availability of thimerosal preservative-free hepatitis B vaccine. MMWR Morbid Mortal Wkly Rep 49 (2000) 642-651
46. McQuillan G.M., Coleman P.J., Kruszon-Moran D., Moyer L.A., Lambert S.B., and Margolis H.S. Prevalence of hepatitis B virus infection in the United States. the National Health and Nutrition Examination Surveys, 1976 through 1994. Am J Public Health 89 (1999) 14-18
47. Patrick D., Tyndall M., Cornelisse P., Li K., and Sherlock C. Incidence of hepatitis C virus infection among injection drug users during an outbreak of HIV infection. CMAJ 165 (2001) 889-895
48. Schilicting E., Johnson M., Brems C., Wells R., Fisher D., and Reynolds G. Validity of injecting drug users' self report of hepatitis A, B, and C. Clin Lab Sci 16 (2003) 99-106
49. Jose B., Friedman S., and Flom P. Self-report validity of hepatitis B infection and vaccination among youth. [abstract]. The 128th Annual Meeting of APHA (2000)
50. Griffiths D. A catalytic model of infection for measles. Appl Stat 23 (1974) 330-339
51. Muench H. Catalytic models in epidemiology (1959), Harvard University Press, Cambridge MA
52. Coleman P.J., McQuillan G.M., Moyer L.A., Lambert S.B., and Margolis H.S. Incidence of hepatitis B virus infection in the United States, 1976-1994. estimates from the National Health and Nutrition Examination Surveys. J Infect Dis 178 (1998) 954-959
53. Centers for Disease Control and Prevention. CDC Vaccine Price List (2000). http://www.cdc.gov/nip/vfc/cdc_vac_price_list.htm#pediatric Available at: http://www.cdc.gov/nip/vfc/cdc_vac_price_list.htm#pediatric. Accessed June
54. Brooks E.A., Lacey L.F., Payne S.L., and Miler D.W. Economic evaluation of lamivudine compared with interferon-alpha in the treatment of chronic hepatitis B in the United States. Am J Manag Care 7 (2001) 677-682
55. Bennett W.G., Inoue Y., Beck J.R., Wong J.B., Pauker S.G., and Davis G. Estimates of the cost-effectiveness of a single course of interferon-alpha2b in patients with histologically mild chronic hepatitis C. Ann Intern Med 127 (1997) 855-865
56. Zhou F., Euler G.L., McPhee S.J., et al. Economic analysis of promotion of hepatitis B vaccinations among Vietnamese-American children and adolescents in Houston and Dallas. Pediatrics 111 6 Pt 1 (2003) 1289-1296
57. U.S. Department of Labor. Bureau of Labor Statistics. Washington DC, 2004. Available at: http://www.bls.gov/cpi/home.htm. Accessed June 20, 2004.
58. Gold M.R., Siegel J.E., Russell L.B., and Weinstein M.C. Cost-effectiveness in health and medicine (1996), Oxford University Press, New York
59. Salzmann P., Kerlikowske K., and Phillips K. Cost-effectiveness of extending screening mammography guidelines to include women 40 to 49 years of age. Ann Intern Med 127 (1997) 955-965
60. Mandelblatt J. Benefits and costs of using HPV testing to screen for cervical cancer. JAMA 287 (2002) 2372-2381
61. Centers for Disease Control and Prevention. Prevalence of hepatitis C virus infection among clients of HIV counseling and testing sites-Connecticut, 1999. MMWR Morb Mortal Wkly Rep 50 (2001) 577-581